Carcinomatous meningitis (CM) is a severe complication of lung cancer. Here, we report on two EGFR-mutated patients who attained relatively long survivals by erlotinib treatment after diagnosis of CM. The first case is a 59-year-old woman who was diagnosed as adenocarcinoma harboring an EGFR mutation (L858R); her disease was at stage IV with multiple brain metastases. The time from the initial diagnosis of lung cancer to CM was 364 days. Erlotinib was administered for 5 months, and the survival time from the diagnosis of CM was 278 days. The second case is a 60-year-old man who underwent right lower lobe lobectomy and was diagnosed as adenocarcinoma with an EGFR mutation (E746-750 deletion) and at the pathological stage IIA (pT1N2M0). Later, the disease was recurring as brain metastasis, and progressed to CM 637 days after diagnosis of lung cancer. Erlotinib was administered for 5.5 months, and the survival time from the diagnosis of CM was 281 days. These cases indicate that erlotinib is a reasonable option for the treatment of CM in EGFR-mutated patients.
Introduction
Carcinomatous meningitis (CM) is a severe complication of lung cancer. The frequency of CM in solid tumors is approximately 5-10%, which has gradually been increasing 1, 2, 3) , with lung and breast cancer being the most common primary malignancies 4) . The treatment of CM in advanced non-small cell lung cancer (NSCLC) is not satisfactory because there is no standard treatment for CM available and there is limited survival; the median survival ranges from 4 to 9 weeks 5, 6) . However, recent reports have described good responses in NSCLC patients with epidermal growth factor receptor (EGFR) mutations, treated with EGFR-tyrosine kinase inhibitors (TKIs). Gefitinib was the first TKI that was shown to provide dramatic responses in those patients. Nevertheless, after a median period of about 10 months 7) , the disease in the majority of the patients eventually progressed. The brain is a common metastatic site of NSCLC, and it is similar after using gefitinib. Though erlotinib is also an EGFR TKI with an activity similar to that of gefitinib, some reports have shown that erlotinib is a reasonable option for the treatment of brain metastasis and CM 8) . Here, we report on two cases that attained relatively long survivals after the diagnosis of CM.
Case presentation
The first case is a 59-year-old woman, who had never smoked, who suffered from back pain and numbness in the left little finger. Chest X ray and a computed tomography (CT) scan revealed right pulmonary nodules. Magnetic resonance imaging (MRI) of the brain showed multiple brain metastases. A pathological diagnosis of adenocarcinoma with an EGFR mutation (L858R) was established by transbronchial biopsy. The patient's staging was IV with multiple brain metastases as well as bone metastasis (Fig. 1) .
She received gefitinib for 11 months, 250 mg/day for the first 39 days, then every other day because of liver dysfunction. And whole brain radiotherapy (total 30Gy: 3Gy/fraction) was done from the day following the di- 3) Department of Thoracic Surgery, Saitama Medical University International Medical Center agnosis. Then, radiotherapy for bone metastasis was administered, and zoledroic acid was injected. She continued to take gefitinib for a total of 12 months, at which point the progression of her disease was diagnosed. Her chest CT scan revealed an increase in the size of a pulmonary nodule. PET showed bone metastasis of a new lesion. Subsequent brain MRI revealed diffuse leptomeningeal disease prominent in the cerebellum, which was diagnosed as CM (Fig. 2) . She received 1 cycle of a combination chemotherapy consisting of carboplatin and paclitaxel, but, because of side effects, we had to change the treatment to erlotinib, which made CM a stable dis- ease without acute progression. Erlotinib was continued for 5 months. The time from the initial diagnosis of lung cancer to CM was 364 days, and the survival time from the diagnosis of CM was 278 days.
The second case is a 60-year-old man who smoked 800 pack-years and presented with abnormality on a chest X ray in a health examination at his company. Chest X ray and CT scan revealed a pulmonary nodule in the right lung. No metastasis was found, and the staging was Stage Ib (cT2N0M0) (Fig. 3) . A right lower lobe lobectomy was done, and the final diagnosis and pathological staging were adenocarcinoma with EGFR mutation (E746-750 deletion) and Stage IIA (pT1N2M0). As an adjuvant therapy, he received chemotherapy consisting of carboplatin and docetaxel, concurrent with radiotherapy of the mediastinum (total 60Gy, 2Gy/fraction). After radiotherapy, the chemotherapy was stopped after 2 cycles because the patient had developed irradiation pneumonitis.
At 13 months from the diagnosis of lung cancer, brain MRI revealed multiple brain metastases. He then received gefitinib 250 mg/day for 5 months, then every other day for 3 months because of side effects in the skin. At 18 months after the initial diagnosis, he presented with nausea, disorientation and diplopia. Subsequent brain MRI revealed high intensity signals in sulcus of the cerebellum, which showed CM (Fig. 4) . He received whole brain radiotherapy (total 30Gy, 3Gy/fraction) and erlotinib 150 mg/day for 2 weeks, and then received erlotinib 100 mg/day for 4 months because of nausea and diarrhea. At 23 months, the disease was progressing with ascites and peritoneal metastasis, and we changed erlotinib to pemetrexed, 3 cycles. He subsequently received erlotinib again for 1 month. The time from diagnosis of lung cancer to CM was 637 days, and the survival time from the diagnosis of CM was 281 days.
Discussion
From 2007 to 2012, a total of 2,190 patients with NSCLC were treated in our institution, and there were 8 patients with CM (Table 1) . Of the 8 patients with CM, there were 5 patients with EGFR mutations, none of whom had the T790M second mutation at the diagnosis of CM. One, two, and two patients were treated by erlotinib, gefitinib, and both, respectively, before diagnosis of CM (Table 2) . Only the two patients, who had received gefitinib before diagnosis of CM were treated by erlotinib after diagnosis of CM. These two patients had relatively long survival times after diagnosis of CM.
The prognosis of patients with CM associated with lung cancer is still very poor. But there are case reports on gefitinib and erlotinib being effective on metastatic lesions in the central nervous system. Our two patients received gefitinib before being diagnosed with CM, and after the CM diagnosis they received erlotinib (Table 2) . Whole brain radiotherapy was combined with erlotinib when they were diagnosed with brain metastases.
There are several reports published on disease control in connection with erlotinib administration after gefitinib treatment, with response rates ranging from 9.5-14% 9, 10) . But if the patients have never been treated by erlotinib when CM is diagnosed, erlotinib is an option to control CM. Thus, animal studies have revealed that the blood brain barrier (BBB) hinders the delivery of gefitinib to tumor cells in the central nervous system (CNS). Therefore, the tumor cells in the CNS would not become tolerant to TKI because of administration of gefitinib and remain sensitive to erlotinib, which penetrates the BBB to some extent because of its relatively higher serum con- centration compared with that of gefitinib 11) . Radiotherapy for CM was reported to be both feasible and effective in relieving symptoms 1, 12) , although some reports found that whole brain radiotherapy for CM in patients with NSCLC did not prolong survival 13, 14) . In our two cases, whole brain radiotherapy was administered when brain metastasis was revealed, but before CM was diagnosed, And to improve the CM patients with lung cancer, EGFR-TKI treatment, especially erlotinib, combined with radiotherapy of the brain may be a therapeutic approach. Further studies and reports are needed in order to clarify the effect and the timing of radiotherapy to the brain in regard to the kinetics of EGFR-TKI.
